NCT02884635已完成2 期
Phase IIa Study of ASP1707 A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Phase 2a Study of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 27
- 主要终点
- ACR20 response rate
研究概览
简要总结
The objective of this study is to evaluate the efficacy, pharmacokinetics, pharmacodynamics and safety of ASP1707 in combination with MTX in postmenopausal female patients with RA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subject has RA that was diagnosed according to the 1987 ACR criteria or the 2010 ACR/EULAR criteria.
- •Subject meets the ACR 1991 Revised Criteria for the Classification of Global Functional Status in RA Class I, II or, III.
- •subject has active RA as evidenced by both of the followings:
- •≥ 6 tender/painful joints (using 68-joint assessment)
- •≥ 6 swollen joints (using 66-joint assessment)
- •CRP (C-reactive protein) of > 0.3 mg/dL or ESR (Erythrocyte sedimentation rate) of > 28 mm/hr at screening.
- •Subject who continuously received MTX and who is able to continue stable dose of MTX.
- •Subject who did not receive the following drugs, or received the drugs with stable dosage:
- •Non-steroidal anti-inflammatory drugs, oral morphine or equivalent opioid analgesics, acetaminophen, or oral corticosteroids.
排除标准
- •Inadequate responders to a biologic DMARD (Disease-modifying antirheumatic drug).
- •Subject has taken other investigational research products are prohibited within 12 weeks (84 days) or within 5 half-lives, whichever is longer, prior to screening.
- •Subject has undergone surgery which has residual effects on the assessed joints, or is scheduled to undergo surgery that may affect the study evaluation of the assessed joints.
- •Subject has another type of inflammatory arthritis other than RA.
- •Subject who meets any of the following criteria of laboratory values at screening:
- •White blood cell count <4000/μL
- •Platelet count <100000/μL
- •ALT (Alanine Aminotransferase) ≥ 2 x ULN (Upper Limit of Normal)
- •AST (Aspartate Aminotransferase) ≥ 2 x ULN
- •Total bilirubin ≥ 1.5 x ULN
- •Positive Hepatitis B surface antigen, Hepatitis B virus-DNA quantitation, or Hepatitis C virus antibody
- •Subject has a positive QuantiFERON-TB Gold test or T-spot.
- •Subject has a history of or concurrent malignant tumor.
- •Subject has any ongoing severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, neurological, infectious, or autoimmune disease except for RA, or diseases which preclude the subject's participation in the study.
- •Subject has a history of clinically significant allergy.
- •Subject has clinically significant abnormalities on the 12-lead Electrocardiogram.
- •Subject has a history of positive Human Immunodeficiency Virus infection.
研究组 & 干预措施
ASP1707
Experimental
ASP1707 will be orally administered for 12 weeks.
干预措施: ASP1707 (Drug)
ASP1707
Experimental
ASP1707 will be orally administered for 12 weeks.
干预措施: Methotrexate (Drug)
Placebo
Placebo Comparator
Placebo will be orally administered for 12 weeks.
干预措施: Placebo (Drug)
Placebo
Placebo Comparator
Placebo will be orally administered for 12 weeks.
干预措施: Methotrexate (Drug)
结局指标
主要结局
ACR20 response rate
时间窗: Week 12
ACR20: American College of Rheumatology 20
次要结局
- ACR50 response rate(Up to Week 12)
- Percentage of subjects achieving EULAR response criterion of "Good Response"(Up to Week 12)
- Change from baseline in Tender Joint Count (68 joints)(Baseline and Up to Week 12)
- Change from baseline in Swollen Joint Count (66 joints)(Baseline and Up to Week 12)
- Change from baseline in CRP(Baseline and Up to Week 12)
- ACR20 response rate(Up to Week 8)
- Percentage of subjects achieving DAS28-CRP score and DAS28-ESR score for remission (<2.6)(Up to Week 12)
- Percentage of subjects achieving DAS28-CRP score and DAS28-ESR score for low disease activity (≤3.2)(Up to Week 12)
- ACR70 response rate(Up to Week 12)
- Change from baseline in ESR(Baseline and Up to Week 12)
- Safety assessed by incidence of adverse events(Up to Week 13)
- Safety assessed by pulse rate(Up to Week 13)
- Safety assessed by laboratory tests: Hematology(Up to Week 13)
- Safety assessed by laboratory tests: Biochemistry(Up to Week 13)
- Safety assessed by laboratory tests: Urinalysis(Up to Week 13)
- Change from baseline in DAS28-CRP score(Baseline and Up to Week 12)
- Change from baseline in DAS28-ESR score(Baseline and Up to Week 12)
- Change from baseline in the SDAI score(Baseline and Up to Week 12)
- Safety assessed by body temperature(Up to Week 13)
- Safety assessed by standard 12-lead electrocardiogram(Up to Week 13)
- Safety assessed by weight(Up to Week 13)
- Pharmacodynamics assessed by plasma concentration of TNF-α(Up to Week 13)
- Percentage of subjects achieving ACR/EULAR score for remission(Up to Week 12)
- Percentage of subjects achieving SDAI score ≦ 3.3 (SDAI remission)(Up to Week 12)
- Plasma concentration of metabolite of ASP1707(Up to Week 12)
- Pharmacodynamics assessed by endocrinology tests(Up to Week 13)
- Percentage of subjects achieving EULAR response criterion of "Good Response" or "Moderate Response"(Up to Week 12)
- Change from baseline for the HAQ-DI(Baseline and Up to Week 12)
- Safety assessed by blood pressure in sitting position(Up to Week 13)
- Pharmacodynamics assessed by plasma concentration of MMP3(Up to Week 13)
- Plasma concentration of ASP1707(Up to Week 12)
- Pharmacodynamics assessed by plasma concentration of IL-6(Up to Week 13)
研究者
研究点 (27)
Loading locations...
相似试验
已完成
2 期
A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic PainEndometriosisNCT01767090Astellas Pharma Europe B.V.912
已完成
1 期
Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female SubjectsHealthy VolunteersNCT03183739Astellas Pharma Inc36
已完成
1 期
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 AntigenAdvanced MalignanciesAdvanced CancerNCT04837196Astellas Pharma Global Development, Inc.24
已完成
2 期
A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the KneeOsteoarthritis of the KneeChronic Lower Back PainNCT02611466Astellas Pharma Europe B.V.215
已完成
2 期
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" EpisodesIdiopathic Parkinson's DiseaseNCT01617135Acorda Therapeutics25